EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models

Raphael S. Werner, Jae-Hwi Jang, Markus Rechsteiner, Michaela B. Kirschner, Isabelle Opitz

Organoids · 09.11.2024 · 3 (4) · 281-294

DOI: 10.3390/organoids3040017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organoids, online erschienen am 09.11.2024. Verfasst von Raphael S. Werner und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iten-Kohaut Foundation, Kurt und Senta Herrmann Foundation, Stiftung für angewandte Krebsforschung (SAKF) Zurich.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent advances in the personalized treatment of non-small cell lung cancer (NSCLC) require representative in vitro model systems that reflect tumor heterogeneity and maintain the characteristic genetic aberrations. We therefore aimed to establish patient-derived NSCLC organoids that offer a reliable platform for further investigations.

Methods

NSCLC organoids were cultured between May 2020 and February 2022 from surgically resected NSCLC tissue specimens. After histological and immunohistochemical validation, genetic validation was performed by targeted next-generation sequencing of tissue and organoid specimens using the Oncomine Focus Assay (ThermoFisher Scientific).

Results

From 37 resected NSCLC samples, 18 primary organoid cultures were successfully established and expanded during early passages. Upon histomorphological validation, organoids showed complementary characteristics when compared to the resected parental tumor, including adenocarcinoma, squamous cell carcinoma, mucoepidermoid carcinoma, and lung carcinoid differentiation. Among nine parental tumors, traceable genetic alterations were detected, and three corresponding organoids lines retained this mutational profile, including a KRAS p.Gly12Val mutation, KRAS p.Gly12Cys mutation, and RET-fusion.

Conclusions

The establishment of primary NSCLC organoids from surgically resected tissue is feasible. Histological, immunohistochemical, and genetic validation is essential to identify representative NSCLC organoids that maintain the characteristics of the parental tumor. Overall, low establishment rates remain a challenge for broad clinical applications.

Förderung

  • Iten-Kohaut Foundation
  • Kurt und Senta Herrmann Foundation
  • Stiftung für angewandte Krebsforschung (SAKF) Zurich

Zitieren

APA

Werner, R. S., Jang, J., Rechsteiner, M., Kirschner, M. B., & Opitz, I. (2024). Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models. Organoids, 3(4), 281-294. https://doi.org/10.3390/organoids3040017

Vancouver

Werner RS, Jang J, Rechsteiner M, Kirschner MB, Opitz I. Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models. Organoids. 2024;3(4):281-294. doi:10.3390/organoids3040017

BibTeX
@article{Werner2024,
  author = {Werner, Raphael S. and Jang, Jae-Hwi and Rechsteiner, Markus and Kirschner, Michaela B. and Opitz, Isabelle},
  title = {Establishment and Validation of Patient-Derived Non-Small Cell Lung Cancer Organoids as In Vitro Lung Cancer Models},
  journal = {Organoids},
  year = {2024},
  volume = {3},
  number = {4},
  pages = {281--294},
  doi = {10.3390/organoids3040017}
}
Kostenlos starten →